Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia: Case Report and Review of Literature

J Pediatr Hematol Oncol. 2020 Aug;42(6):e469-e471. doi: 10.1097/MPH.0000000000001508.

Abstract

Invasive aspergillosis in hematologic pediatric patients is an opportunistic infection that is difficult to treat, with a high mortality rate when localized in the central nervous system. We are describing a 3-year-old girl who was affected by acute lymphoblastic leukemia who developed cerebral and pulmonary aspergillosis during induction chemotherapy. The patient failed first-line voriconazole treatment because of being a CYP2C19 ultrarapid metabolizer and received effective isavuconazole therapy with no notable side effects.

Publication types

  • Case Reports

MeSH terms

  • Antifungal Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Aspergillus / drug effects*
  • Aspergillus / isolation & purification
  • Child, Preschool
  • Female
  • Humans
  • Neuroaspergillosis / chemically induced
  • Neuroaspergillosis / drug therapy*
  • Neuroaspergillosis / pathology
  • Nitriles / therapeutic use*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Prognosis
  • Pulmonary Aspergillosis / chemically induced
  • Pulmonary Aspergillosis / drug therapy*
  • Pulmonary Aspergillosis / pathology
  • Pyridines / therapeutic use*
  • Triazoles / therapeutic use*

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • isavuconazole